Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

IGC Pharma Yönetim

Yönetim kriter kontrolleri 1/4

IGC Pharma's CEO is Ram Mukunda, appointed in Apr 2005, has a tenure of 19.5 years. total yearly compensation is $1.82M, comprised of 19.8% salary and 80.2% bonuses, including company stock and options. directly owns 5.76% of the company’s shares, worth $1.86M. The average tenure of the management team and the board of directors is 6.8 years and 2.8 years respectively.

Anahtar bilgiler

Ram Mukunda

İcra Kurulu Başkanı

US$1.8m

Toplam tazminat

CEO maaş yüzdesi	19.8%
CEO görev süresi	19.5yrs
CEO sahipliği	5.8%
Yönetim ortalama görev süresi	6.8yrs
Yönetim Kurulu ortalama görev süresi	2.8yrs

Son yönetim güncellemeleri

Recent updates

Does India Globalization Capital's (NYSEMKT:IGC) CEO Salary Compare Well With Industry Peers?

Feb 27

CEO Tazminat Analizi

Ram Mukunda'un ücretlendirmesi IGC Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$13m
Mar 31 2024	US$2m	US$360k	-US$13m
Dec 31 2023	n/a	n/a	-US$14m
Sep 30 2023	n/a	n/a	-US$11m
Jun 30 2023	n/a	n/a	-US$11m
Mar 31 2023	US$1m	US$360k	-US$12m
Dec 31 2022	n/a	n/a	-US$14m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$16m
Mar 31 2022	US$6m	US$320k	-US$15m
Dec 31 2021	n/a	n/a	-US$11m
Sep 30 2021	n/a	n/a	-US$11m
Jun 30 2021	n/a	n/a	-US$9m
Mar 31 2021	US$801k	US$292k	-US$9m
Dec 31 2020	n/a	n/a	-US$9m
Sep 30 2020	n/a	n/a	-US$8m
Jun 30 2020	n/a	n/a	-US$8m
Mar 31 2020	US$719k	US$300k	-US$7m
Dec 31 2019	n/a	n/a	-US$6m
Sep 30 2019	n/a	n/a	-US$5m
Jun 30 2019	n/a	n/a	-US$5m
Mar 31 2019	US$712k	US$300k	-US$4m
Dec 31 2018	n/a	n/a	-US$3m
Sep 30 2018	n/a	n/a	-US$2m
Jun 30 2018	n/a	n/a	-US$2m
Mar 31 2018	US$469k	US$300k	-US$2m

Tazminat ve Piyasa: Ram's total compensation ($USD1.82M) is above average for companies of similar size in the US market ($USD667.78K).

Tazminat ve Kazançlar: Ram's compensation has increased whilst the company is unprofitable.

CEO

Ram Mukunda (65 yo)

19.5yrs

Görev süresi

US$1,821,000

Tazminat

Mr. Ram Mukunda is the Founder of IGC Pharma, Inc. (formerly known as India Globalization Capital, Inc.) and has been Chief Executive Officer, President and Executive Director since April 29, 2005. He is r...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ram Mukunda	President	19.5yrs	US$1.82m	5.76% $ 1.9m
Claudia Grimaldi	VP, Principal Financial Officer	6.4yrs	US$717.00k	1.37% $ 442.7k
Benysh Qureshi	Director of Operations	less than a year	Veri yok	Veri yok
Rohit Goel	Senior Director of Accounting & Principal Accounting Officer	7.1yrs	US$41.00k	Veri yok

6.8yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: IGC's management team is seasoned and experienced (6.8 years average tenure).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ram Mukunda	President	19.5yrs	US$1.82m	5.76% $ 1.9m
Claudia Grimaldi	VP, Principal Financial Officer	2.6yrs	US$717.00k	1.37% $ 442.7k
Richard Prins	Independent Chairman of the Board	17.4yrs	US$259.00k	1.38% $ 445.2k
Terry Lierman	Independent Director	less than a year	US$49.00k	0.038% $ 12.4k
James Moran	Independent Director	2.8yrs	US$185.00k	1.25% $ 402.3k

2.8yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IGC's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

IGC Pharma Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Independent Director recently bought US$200k worth of stock

Independent Chairman of the Board notifies of intention to sell stock

IGC Pharma, Inc., Annual General Meeting, Aug 23, 2024

IGC Pharma, Inc., Annual General Meeting, Aug 23, 2024

President notifies of intention to sell stock

Igc Pharma, Inc. Appoints Terry Lierman as Independent Director to Its Board of Directors

Recent updates

Independent Director recently bought US$200k worth of stock

IGC Pharma, Inc. Advances IGC-AD1 Toward Clinical Trials as a Potential Anti-Amyloid Plaque Treatment for Alzheimer's Disease

Consensus revenue estimates decrease by 21%

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

IGC Pharma, Inc. Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist

Independent Chairman of the Board notifies of intention to sell stock

First quarter 2025 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates increase by 12%

IGC Pharma, Inc., Annual General Meeting, Aug 23, 2024

IGC Pharma's Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

IGC Pharma, Inc., Annual General Meeting, Aug 23, 2024

Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat

IGC Pharma, Inc.'S TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, A Key Hallmark of Alzheimer's Disease

IGC Pharma, Inc. Announces Patient Enrollment At Neurostudies in Phase 2 Trial Investigating IGC-AD1

IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer’S At Week Two Compared to Placebo

New minor risk - Share price stability

IGC Pharma, Inc. announced that it expects to receive $3 million in funding from Bradbury Asset Management (Hong Kong) Limited

IGC Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $6.24051 million.

President notifies of intention to sell stock

Igc Pharma, Inc. Appoints Terry Lierman as Independent Director to Its Board of Directors

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

IGC Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $5.309602 million.

Igc Pharma, Inc. Activates Clincloud, One of 12 Sites in Ongoing Phase 2B Alzheimer’S Trial

New major risk - Financial position

Second quarter 2024 earnings released: US$0.045 loss per share (vs US$0.047 loss in 2Q 2023)

IGC Pharma Expands Phase 2 Trial of IGC-Ad1 to Include the University of Puerto Rico

IGC Pharma, Inc. Presents 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International Conference

IGC Pharma, Inc. announced that it expects to receive $3 million in funding from Bradbury Asset Management (Hong Kong) Limited and other investors

IGC Pharma, Inc. announced delayed annual 10-K filing

Third quarter 2023 earnings released: US$0.042 loss per share (vs US$0.047 loss in 3Q 2022)

India Globalization Capital, Inc. Receives No Objection Letter from Health Canada

India Globalization Capital, Inc. Announces Board Changes

India Globalization Capital, Inc. Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease

Second quarter 2023 earnings released: US$0.047 loss per share (vs US$0.087 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.054 loss per share (vs US$0.037 loss in 1Q 2022)

India Globalization Capital, Inc., Annual General Meeting, Sep 09, 2022

Full year 2022 earnings released: US$0.30 loss per share (vs US$0.21 loss in FY 2021)

India Globalization Capital, Inc. Receives U.S. Patent for Method and Composition for Treating Seizure Disorders

India Globalization Capital, Inc. Announces Final Approval of Settlement of Shareholder Class Action Lawsuits

The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. Common Stock

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. Common Stock

India Globalization Capital, Inc. Announces Positive Primary Endpoint Data for Its Phase 1 Clinical Trial for IGC-AD1

India Globalization Capital, Inc. Announces Preliminary Results for its Exploratory Endpoints from its Phase 1 IGC-AD1 Clinical Trial

India Globalization Capital, Inc. to Present Preliminary Positive Secondary End Point Findings from its Phase 1 Clinical Trial for IGC-AD1

Second quarter 2022 earnings released: US$0.087 loss per share (vs US$0.04 loss in 2Q 2021)

Independent Chairman of the Board notifies of intention to sell stock

India Globalization Capital, Inc. Completes Its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability

First quarter 2022 earnings released: US$0.037 loss per share (vs US$0.047 loss in 1Q 2021)

India Globalization Capital, Inc Announces Issuance of Patent for the Treatment of Alzheimer’S Disease Using THC

India Globalization Capital, Inc. Completes the Final Cohort of its Phase 1 Clinical Trial on Alzheimer’s Patients

Full year 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in FY 2020)

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

India Globalization Capital, Inc. Completes Cohort 1 of Its Phase 1 Thc-Based Clinical Trial on Alzheimer’S Patients

Independent Chairman of the Board recently sold US$90k worth of stock

Independent Chairman of the Board notifies of intention to sell stock

Does India Globalization Capital's (NYSEMKT:IGC) CEO Salary Compare Well With Industry Peers?

India Globalization Capital, Inc. Provides Update on Phase 1 Clinical Trial on Alzheimer’S Patients

Third quarter 2021 earnings released: US$0.056 loss per share (vs US$0.041 loss in 3Q 2020)

India Globalization Capital, Inc. Approves the Election of John E. Lynch to the Board of Directors

India Globalization Capital, Inc., Annual General Meeting, Jan 11, 2021

India Globalization Capital, Inc. Commences Phase 1 of Cannabinoid Clinical Trial for Alzheimer’S Patients

India Globalization Capital, Inc. announced delayed 10-Q filing

India Globalization Capital, Inc. announced delayed 10-Q filing

India Globalization Capital, Inc.(AMEX:IGC) dropped from Russell Microcap Index

India Globalization Capital, Inc. announced delayed annual 10-K filing

CEO Tazminat Analizi

CEO

Görev süresi